异基因干细胞移植作为套细胞淋巴瘤一线治疗的一部分
这项多中心前瞻性试验评估了25例年轻套细胞淋巴瘤患者在一线治疗中接受BEAM-Campath方案预处理异基因干细胞移植的可行性。中位随访60.5个月,2年无进展生存率和总生存率分别为68%和80%,5年分别为56%和76%,9例(38%)发生急性移植物抗宿主病,14例(58%)发生慢性移植物抗宿主病。作者认为一线异基因干细胞移植可行,但仅应考虑用于常规治疗后早期进展高风险的患者。
要点
- 25例年轻套细胞淋巴瘤患者一线接受BEAM-Campath预处理异基因移植,24例植入成功,100天内无非复发死亡事件。
- 中位随访60.5个月,2年无进展生存率68%、总生存率80%,5年分别为56%和76%。
- 9例(38%)发生急性GVHD,14例(58%)发生慢性GVHD(其中8例为广泛型)。
核心结论
- 一线异基因干细胞移植可行,但仅应考虑用于常规治疗后早期进展高风险的患者。
研究设计与样本
- 多中心前瞻性试验,25例年轻套细胞淋巴瘤患者在一线治疗中接受异基因干细胞移植。
- 预处理方案为BEAM(卡莫司汀、依托泊苷、阿糖胞苷、美法仑)-Campath,供者包括同胞供者和无关供者,诱导治疗采用宽松策略。
主要发现
- 25例中24例植入成功,100天内无非复发死亡事件。
- 中位随访60.5个月,共6例死亡,其中3例死于套细胞淋巴瘤。
- 2年无进展生存率和总生存率分别为68%和80%,5年分别为56%和76%。
- 同胞移植与无关供者移植的无进展生存率非常相似,移植前缓解状态不同的患者之间无进展生存率无差异。
- 9例(38%)发生急性移植物抗宿主病,14例(58%)发生慢性移植物抗宿主病,其中8例为广泛型。
临床怎么用
- 作者认为一线异基因干细胞移植可行,但仅应考虑用于常规治疗后早期进展高风险的患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Mantle cell lymphoma (MCL) is an aggressive form of non-Hodgkin lymphoma that remains incurable for the majority of patients. Allogeneic stem cell transplantation (alloSCT) produces long-term disease-free remissions for around 30-40% patients, however it is reserved for the treatment of relapsed disease. This study examined the use of front line transplantation for young patients in an attempt to improve outcomes. Twenty-five patients received an alloSCT using BEAM [BCNU (carmustine), etoposide, cytarabine, melphalan)-Campath conditioning following permissive induction therapy from both related and unrelated donors. This was a multi-centre prospective trial. Twenty-four of 25 patients engrafted with no non-relapse mortality events by day 100. With a median follow-up of 60·5 months, there have been six deaths (3 from MCL). The progression-free survival (PFS) and overall survival were 68% and 80% at 2 years and 56% and 76% at 5 years. PFS was very similar for both sibling and unrelated transplants and there was no difference in PFS between patients with respect to remission status prior to transplantation. Nine (38%) patients experienced acute graft-versus-host disease (GVHD) and 14 (58%) experienced chronic GVHD, of which 8 were extensive. Front line alloSCT is feasible but should only be considered for patients at high risk of early progression following conventional therapy.
引用
- Rule S, Cook G, Russell NH, et al. Allogeneic stem cell transplantation as part of front line therapy for Mantle cell lymphoma. Br J Haematol. 2018. PMID: 30560573. doi:10.1111/bjh.15723
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。